
SOPH Stock Forecast & Price Target
SOPH Analyst Ratings
Bulls say
Sophia Genetics is a leading next-generation sequencing company with a strong and diverse global presence and a potential market value of $40B. Their AI-driven platform is widely used by hospitals and laboratories, and they have a promising partnership with Memorial Sloan Kettering and a new partnership with Mayo Clinic. Despite potential risks, the strong demand for their platform and collaborations in the biopharma industry make SOPHiA's stock a promising investment for future growth.
Bears say
Sophia Genetics is facing several risks that may negatively impact its future performance and profitability. These risks include strong competition in the precision oncology diagnostics market, legal and intellectual property issues, and potential cybersecurity breaches. Additionally, while the company is experiencing growth in its biopharma segment, it still represents less than 10% of total revenue and faces uncertainties surrounding its partnerships with major pharmaceutical companies. Despite its positive outlook on revenue growth and potential profitability in the future, the company's lack of current profitability and uncertainty surrounding its key partnerships makes it a risky investment.
This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.
SOPH Analyst Forecast & Price Prediction
Start investing in SOPH
Order type
Buy in
Order amount
Est. shares
0 shares